ReviewDrugs2017
Teduglutide: A Review in Short Bowel Syndrome.
Review in Drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Pharmacokinetics of Glepaglutide, A Long-Acting Glucagon-Like Peptide-2 Analogue: A Study in Healthy Subjects.Clinical drug investigation · 2022Trial
- Efficacy and safety of teduglutide in children with short bowel syndrome: a narrative review.Pediatric surgery international · 2026Review
- Liver X receptor agonists enhance intestinal repair in neonatal piglets with massive bowel resection.Journal of lipid research · 2026Article
- Double-balloon enteroscopy evaluation and surveillance in patients with short bowel syndrome.Therapeutic advances in gastroenterology · 2026Article
- Real-world effectiveness and safety of teduglutide in adult and pediatric patients with short bowel syndrome in Argentina.World journal of gastrointestinal pharmacology and therapeutics · 2025Article
- Development of a Mechanism of Action-Reflective Cell-Based Reporter Gene Assay for Measuring Bioactivities of Therapeutic Glucagon-like Peptide-2 Analogues.Molecules (Basel, Switzerland) · 2025Article
- Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.Signal transduction and targeted therapy · 2025Review
- Novel homozygous nonsense mutation in glucagon-like peptide-2 receptor gene resulting in severe human illness.JPGN reports · 2024Article
- Evaluation of the Effectiveness of Teduglutide Treatment in Patients with Short Bowel Syndrome in Slovakia-Multicenter Real-World Study.Journal of clinical medicine · 2024Article
- A Systematic Review of Quality of Life in Patients with Short Bowel Syndrome and Their Caregivers.Patient preference and adherence · 2024Review
- An Overview of Short-Bowel Syndrome in Pediatric Patients: Focus on Clinical Management and Prevention of Complications.Nutrients · 2023Review
- Strategies to improve the physicochemical properties of peptide-based drugs.Pharmaceutical research · 2023Review
- GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk.Microorganisms · 2022Review
- Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?Nature reviews. Gastroenterology & hepatology · 2022Review
- Surgical Treatment of Short Bowel Syndrome-The Past, the Present and the Future, a Descriptive Review of the Literature.Children (Basel, Switzerland) · 2022Review
- Therapeutic peptides: current applications and future directions.Signal transduction and targeted therapy · 2022Review
- [Chronic intestinal failure].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2022Article
- HPN Standard of Care and Long-Term Outcomes of CIF Pediatric Patients: Twenty-Eight Years' Experience in a Reference Center.Frontiers in nutrition · 2022Article
- Population pharmacokinetics and exposure-response analyses of teduglutide in adult and pediatric patients with short bowel syndrome.Clinical and translational science · 2021Article
- Nutritional and pharmacological strategy in children with short bowel syndrome.Pediatric surgery international · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subcutaneous teduglutide (Revestive
Indexed as
Identifiers
28194723What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.